Journal of Cardiac Failure
Volume 16, Issue 5 , Pages 419-431 , May 2010

The Critical Link of Hypervolemia and Hyponatremia in Heart Failure and the Potential Role of Arginine Vasopressin Antagonists

  • Jalal K. Ghali, MD

      Affiliations

    • Detroit Medical Center, Detroit, MI
    • Corresponding Author InformationReprint requests: Jalal K. Ghali, MD, DMC Cardiovascular Institute, Harper University Hospital, 3990 John R, Suite 9370, Detroit, MI 48201. Tel: 313-745-7061
    • ,
  • S. William Tam, PhD

      Affiliations

    • Dover, MA

Received 14 August 2009 ,Revised 25 November 2009 ,Accepted 30 December 2009.

References 

  1. Schrier RW. Water and sodium retention in edematous disorder: role of vasopressin and aldosterone. Am J Med. 2006;119:S47–S53
  2. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987;31:1402–1415
  3. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. New Engl J Med. 1984;310:347–352
  4. Ghali JK. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology. 2008;111:147–157
  5. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847–858
  6. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273–F278
  7. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151–2159
  8. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association Functional Class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615–1621
  9. Ghali JK, Cooper RS, Ford E. Hospitalization for heart failure. Arch Intern Med. 1992;152:649–655
  10. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson B, Flegal K, et al. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181
  11. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J AM Coll Cardiol. 2008;52:428–434
  12. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30–S35
  13. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003;337:169–172
  14. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009;122:857–865
  15. Movig KL, Leufkens HG, Lenderink AW, Egberts AC. Validity of hospital discharge international classification of diseases (ICD) codes for identifying patients with hyponatremia. J Clin Epidemiol. 2003;56:530–535
  16. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–463
  17. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC The study group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–474
  18. Tavazzi L, Maggioni AP, Lucci D, Cacciatore G, Ansalone G, Oliva F, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J. 2006;27:1207–1215
  19. Zannad F, Mebazaa A, Juillère Y, Cohen-Solal A, Guize L, Alla F, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail. 2006;8:697–705
  20. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980–988
  21. Hesse B, Nielsen I, Bollerup AC, Olesen KH, Uhrenholdt A. Hemodynamics, compartments and the renin-aldosterone system in chronic heart failure. Eur J Cardiol. 1975;3:107–115
  22. Levine TB, Franciosa JA, Vrobel T, Cohn HN. Hyponatremia as a marker for high renin heart failure. Br Heart J. 1982;47:161–166
  23. Packer M, Medina Y, Yushak M. Relationship between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol. 1984;3:1035–1043
  24. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohormonal activation and responses to orthostasis. J Clin Endocrinol Metab. 1984;59:924–930
  25. Brown JJ, Davies DL, Johnson VW, Lever AF, Robertson JI. Renin relationships in congestive cardiac failure, treated and untreated. Am Heart J. 1970;80:329–342
  26. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;6:1385–1390
  27. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–1729
  28. Szatalowicz VL, Arnold PE, Chainovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremia patients with congestive heart failure. N Engl J Med. 1981;305:263–266
  29. Riegger GAJ, Leibau F, Koschsick K. Antidiuretic hormone in congestive heart failure. Am J Med. 1982;72:49–52
  30. Leaf A, Mamby AR. An antidiuretic mechanism not regulated by extracellular fluid toxicity. J Clin Invest. 1952;31:60–71
  31. Weston RE, Grossman J, Borun ER, Hanenson IB. The pathogenesis and treatment of hyponatremia in congestive heart failure. Am J Med. 1958;25:558–572
  32. Guyton AC. The body fluids and kidneys. In:  Guyton AC,  Hall JE editor. Textbook of Medical Physiology. Philadelphia (PA): WB Saunders Company; 2006;p. 291–414
  33. Mitchell LD, Barron K, Brody MJ, Johnson AK. Two possible actions for circulating angiotensin II in the control of vasopressin release. Peptides. 1982;3:503–507
  34. Brooks VL, Keil LC, Reid IA. Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res. 1986;58:829–838
  35. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998;449:481–491
  36. Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol. 1989;257:1228–1234
  37. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem. 1999;195:93–98
  38. Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1a receptor. Eur J Pharmacol. 2000;39:39–48
  39. Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol. 2001;41:175–202
  40. Howl J, Ismail T, Strain AJ, Kirk CJ, Anderson D, Wheatley M. Characterization of the human liver vasopressin receptor: profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function. Biochem J. 1991;276:189–195
  41. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, et al. The vasopressin V1b critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest. 2004;113:302–309
  42. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frøkiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999;10:647–663
  43. Nielsen S. Renal aquaporins: an overview. BJU. 2002;90:1–6
  44. Funayama H, Nakamura T, Saito T, Yoshimura A, Saito M, Kawakami M. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int. 2004;66:1387–1392
  45. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–1589
  46. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine (Balt). 1976;55:121–129
  47. Arieff AI, Guisado R. Effects on the central nervous system of hypernatremic and hyponatremic states. Kidney Int. 1976;10:104–116
  48. Renneboog B, Vendemergel X, Manto MN, et al. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med. 2006;119:71;e1–8
  49. Bennett SJ, Sauvé MJ. Cognitive deficits in patients with heart failure: a review of the literature. J Cardiovasc Nurs. 2003;18:219–242
  50. Vogels RLC, Weinstein HC, Schroeder-Tanka JM. Cognitive impairment in heart failure: a systematic review of literature. Eur J Heart Fail. 2006;5:33–34
  51. Gruhn N, Larsen F, Boesgaard S, et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke. 2001;2:2530–2533
  52. Lee C, Lee J, Kim J, et al. Cerebral metabolic abnormalities in congestive heart failure detected by proton magnetic resonance spectroscopy. J Am Coll Cardiol. 1999;33:1196–1202
  53. Schmidt R, Fazekas F, Offenbacher H, et al. Brain magnetic resonance imaging neuropsychological evaluation of patients with idiopathic dilated cardiomyopathy. Stroke. 1991;22:195–199
  54. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  55. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153:1021–1028
  56. Klein L, O'Connor M, Leimberger D, Gattis-Stough W, Piña IL, Felker GM. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Chronic Heart Failure (OPTIME-CHF) Study. Circulation. 2005;111:2454–2460
  57. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840–847
  58. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971
  59. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–1633
  60. Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med. 2001;2(Suppl 2):S7–S12
  61. Krumholz HM, Chen YT, Bradford WD, Cerese J. Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Managed Care. 1999;5:715–723
  62. Saxon LA, Stevenson WG, Middlekauff HR, Fonarow G, Woo M, Moser D, et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;72:62–65
  63. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257–267
  64. Lee DS, Austin PC, Rouleau JL. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587
  65. Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M, et al. Predictors of short term mortality in heart failure—insights from the Euro Heart Failure survey. Int J Cardiol. 2010;138:63–69
  66. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156:1814–1820
  67. Wong PS, Davidsson GK, Timeyin Warren A, Watson DJ, Vincent R, et al. Heart failure in patients admitted to hospital: mortality is still high. Eur J Intern Med. 2002;13:304–310
  68. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med. 2007;167:1998–2005
  69. Rossi J, Bayram M, Udelson JE, Lloyd-Jones D, Adams KF, Oconnor CM, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care. 2007;9:82–86
  70. Ghali JK. Hyponatremia in heart failure: a call for redefinition. Eur Heart J. 2007;28:920–921
  71. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008;29:285–287
  72. Zoghi M, Duygu H, Güngör H, Nalbantgil S, Yilmaz GM, Tülüce K, et al. The determination of the factors impacting on in-hospital mortality in patients with acute heart failure in a tertiary referral center. Anadolu Kardiyol Derg. 2008;8:255–259
  73. Castro GP, Verdejo PH, Vukasovic RJL, Garcés E, González I. Grupo ICARO. Predictors of hospital death and prolonged hospitalization in patients with cardiac failure in Chilean hospitals. Rev Med Chil. 2006;134:1083–1091
  74. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801–1808
  75. Latado AL, Passos LC, Braga JC, Santos A, Guedes R, Moura SS, et al. Predictors of in-hospital lethality in patients with advanced heart failure. Arq Bras Cardiol. 2006;87:185–192
  76. Brophy JM, Deslauriers G, Rouleau JL. Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol. 1994;10:543–547
  77. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc. 2006;4:1–11
  78. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol. 2008;19:764–770
  79. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24(6):1601–1608
  80. Callahan MA, Do HT, Caplan DW, Yoon-Flannery K. Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study. Postgrad Med. 2009;121:186–191
  81. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112
  82. Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail. 2000;2:305–313
  83. Licata G, Di Pasquale P, Parrinello , Cardinale A, Scandurra A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long term effects. Am Heart J. 2003;145:459–466
  84. Chow KM, Szeto CC, Wong TYH, Leung CB, Li PKT. Risk factors for thiazide-induced hyponatraemia. Q J Med. 2003;96:911–917
  85. Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med. 1984;100:777–782
  86. Francis GS, Siegel RM, Goldsmith SD, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohormonal axis. Ann Intern Med. 1985;103:1–6
  87. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22
  88. Greenberg A. Diuretic complications. Am J Med Sci. 2000;319:10–24
  89. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  90. Weber KT. Furosemide in the long term management of heart failure: the good, the bad and the uncertain. J Am Coll Cardiol. 2004;44:1308–1310
  91. McCurley J, Hanlon S, Shao-kui W, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol. 2004;44:1301–1307
  92. Philbin EF, Cotto M, Rocco TA, Jenkins PL. Association between diuretic use, clinical response and death in acute heart failure. Am J Cardiol. 1997;80:519–523
  93. Rogers HL, Marshall J, Bock J, Dowling TC, Feller E, Robinson S, et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. 2008;14:1–5
  94. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–683
  95. Schrier RW. Role of diminished renal function in cardiovascular mortality marker or pathogenetic factor?. J Am Coll Cardiol. 2006;47:1–8
  96. Ali F, Raufi A, Washington B, Ghali JK. Conivaptan: a vasopressin receptor V1a/V2 antagonist. Cardiovasc Drug Rev. 2007;25:261–279
  97. Yatsu T, Tomura Y, Tahara A, Wada K, Kusayama T, Tsukada J, et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 1999;376:239–246
  98. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  99. Goldsmith SR, Elkayam U, Haught H, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2008;14:641–647
  100. Russell SD, Selaru P, Pyne DA, Ghazzi MM, Massey KD, Pressler M, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose Evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am Heart J. 2003;145:179–186
  101. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Conivaptan Study Group (2007) Assessment of the efficacy and safety of intravenous conivaptan in eubolemic and hypervolemic and hypervolemic. Am J Nephrol 27:447–457.
  102. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, et al. Efficacy and safety of oral conivaptan: V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91:2145–2152
  103. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337:28–36
  104. Verbalis JG, Rosansky S, Wagoner LE, Smith N, Brave A, Andoh M. Conivaptan for the treatment of hyponatremia in hospitalized patients: results from an open label study. Crit Care Med. 2007;34(Suppl):A64
  105. Ghali JK, Verbalis JG, Gross P, Long WA, Smith N. Conivaptan, a novel arginine vasopressin antagonist, increased serum sodium concentration in patients with heart failure and envolemic or hypervolemic hyponatremia. J Am Coll Cardiol. 2006;47:62A;(Suppl A)
  106. Ghali JK, Yan B, McNutt B. Conivaptan a vasopressin-receptor antagonist for the treatment of hyponatremia in patients with and without underlying heart failure. J Cardiac Fail. 2008;14:S76;(Suppl)
  107. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–2696
  108. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure The Everest Clinical Status Trials. JAMA. 2007;297:1332–1343
  109. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA. 2007;297:1319–1331
  110. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–191
  111. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized, double-blind multicenter trial. Gastroenterology. 2003;124:933–939

 Dr. Jalal Ghali: Advisory Panel and Research Grants; Astellas, Otsuka, CardioKline Biogen Idec, Speaker's Bureau; Astellas and Otsuka Dr. S. William Tam: consultant for Biogen Idec and CardioKine, Inc.

PII: S1071-9164(09)01241-X

doi: 10.1016/j.cardfail.2009.12.021

Journal of Cardiac Failure
Volume 16, Issue 5 , Pages 419-431 , May 2010

Article Tools